Hydrogen activates atp-binding cassette transporter a1-dependent efflux ex vivo and improves high-density lipoprotein function in patients with hypercholesterolemia: A double-blinded, randomized, and placebo-controlled trial

Journal of Clinical Endocrinology and Metabolism

Volumn 100, Issue 7, 2015, Pages 2724-2733

  Song, Guohua ^a   Lin, Quanqiang ^a   Zhao, Hui ^a   Liu, Meiyuan ^b   Ye, Fenglong ^a   Sun, Yujuan ^c   Yu, Yang ^a   Guo, Shoudong ^a   Jiao, Peng ^a   Wu, Yun ^a   Ding, Guoyong ^a   Xiao, Qiang ^a   Qin, Shucun ^a  

^a TAISHAN MEDICAL UNIVERSITY   (China)

^b Heart Center of TaiShan Medical University ^*  (China)

^c Tai'An He Ren Tang Hospital   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER A1; APOLIPOPROTEIN B100; APOLIPOPROTEIN M; DRINKING WATER; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROGEN; LOW DENSITY LIPOPROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; PLACEBO; PRE BETA HIGH DENSITY LIPOPROTEIN; ABCA1 PROTEIN, HUMAN;

ADULT; ANIMAL CELL; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; BONE MARROW; CASE CONTROL STUDY; CELL PROTECTION; CHINA; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; DOUBLE BLIND PROCEDURE; DOWN REGULATION; ENDOTHELIUM CELL; EX VIVO STUDY; HUMAN; HUMAN CELL; HYPERCHOLESTEROLEMIA; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; METABOLIC SYNDROME X; MOUSE; NONHUMAN; OXIDATION; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN FUNCTION; RANDOMIZED CONTROLLED TRIAL; UPREGULATION; WESTERN BLOTTING; ANIMAL; BLOOD; CELL CULTURE; DRUG EFFECTS; MACROPHAGE; METABOLISM; MIDDLE AGED; PHYSIOLOGY; TRANSPORT AT THE CELLULAR LEVEL;

ADULT; ANIMALS; ATP BINDING CASSETTE TRANSPORTER 1; BIOLOGICAL TRANSPORT; CASE-CONTROL STUDIES; CELLS, CULTURED; CHINA; DOUBLE-BLIND METHOD; HUMANS; HYDROGEN; HYPERCHOLESTEROLEMIA; LIPOPROTEINS, HDL; MACROPHAGES; MICE; MIDDLE AGED; OXIDATIVE STRESS; PLACEBOS;

EID: 84942694147     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2015-1321     Document Type: Article

References (35)

1. Barter PJ, Brewer HB Jr, Chapman MJ, Hennekens CH, Rader DJ, Tall AR. Cholesteryl ester transfer protein: a novel target for raising HDLand inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol. 2003;23:160-167.
2. KhovidhunkitW,KimMS,MemonRA,et al. Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J Lipid Res. 2004;45:1169-1196.
3. Esteve E, Ricart W, Fernández-Real JM. Dyslipidemia and inflammation: an evolutionary conserved mechanism. Clin Nutr. 2005; 24:16-31.
4. Joy T, Hegele RA. Is raising HDL a futile strategy for atheroprotection? Nat Rev Drug Discov. 2008;7:143-155.
5. Rader DJ. Mechanisms of disease: HDL metabolism as a target for novel therapies. Nat Clin Pract Cardiovasc Med. 2007;4:102-109.
6. Ohsawa I, Ishikawa M, Takahashi K, et al. Hydrogen acts as a therapeutic antioxidant by selectively reducing cytotoxic oxygen radicals. Nat Med. 2007;13:688-694.
7. Amitani H, Asakawa A, Cheng K, et al. Hydrogen improves glycemic control in type 1 diabetic animal model by promoting glucose uptake into skeletal muscle. PLoS One. 2013;8:e53913.
8. Kajiyama S, Hasegawa G, Asano M, et al. Supplementation of hydrogen-rich water improves lipid and glucose metabolism in patients with type 2 diabetes or impaired glucose tolerance. Nutr Res. 2008; 28:137-143.
9. Gharib B, Hanna S, Abdallahi OM, Lepidi H, Gardette B, De Reggi M. Anti-inflammatory properties of molecular hydrogen: investigation on parasite-induced liver inflammation. CRAcad Sci III. 2001; 324:719-724.
10. Song G, Tian H, Qin S, et al. Hydrogen decreases athero-susceptibility in apolipoprotein B-containing lipoproteins and aorta of apolipoprotein E knockout mice. Atherosclerosis. 2012;221:55-65.
11. Zong C, Song G, Yao S, et al. Administration of hydrogen-saturated saline decreases plasma low-density lipoprotein cholesterol levels and improves high-density lipoprotein function in high-fat diet-fed hamsters. Metabolism. 2012;61:794-800.
12. Song G, Li M, Sang H, et al. Hydrogen-rich water decreases serum LDL-cholesterol levels and improves HDL function in patients with potential metabolic syndrome. J Lipid Res. 2013;54:1884-1893.
13. Kontush A, Chapman MJ. Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. Pharmacol Rev. 2006;58:342-374.
14. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 17 2002;106: 3143-3421.
15. Plasma lipoproteins. Part A: preparation, structure, and molecular biology. Methods Enzymol. 1986;128:1-992.
16. Yu Y, Guo S, Feng Y, et al. Phospholipid transfer protein deficiency decreases the content of S1P in HDL via the loss of its transfer capability. Lipids. 2014;49:183-190.
17. Tabas I, Williams KJ, Borén J. Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications. Circulation. 2007;116:1832-1844.
18. Reddy ST, Hama S, Ng C, Grijalva V, Navab M, Fogelman AM. ATP-binding cassette transporter 1 participates inLDLoxidation by artery wall cells. Arterioscler Thromb Vasc Biol. 2002;22:1877-1883.
19. Vuletic S, Dong W, Wolfbauer G, Tang C, Albers JJ. PLTP regulates STAT3 and NFB in differentiated THP1 cells and human monocyte-derived macrophages. Biochim Biophys Acta. 2011;1813: 1917-1924.
20. Rikitake Y, Hirata K, Kawashima S, Akita H, Yokoyama M. Inhibitory effect of inducible type nitric oxide synthase on oxidative modification of low density lipoprotein by vascular smooth muscle cells. Atherosclerosis. 1998;136:51-57.
21. McCrohon JA, Jessup W, Handelsman DJ, Celermajer DS. Androgen exposure increases human monocyte adhesion to vascular endothelium and endothelial cell expression of vascular cell adhesion molecule-1. Circulation. 1999;99:2317-2322.
22. Goff DC Jr, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(25 Suppl 2): S49-S73.
23. Kunitake ST, La Sala KJ, Kane JP. Apolipoprotein A-I-containing lipoproteins with pre-beta electrophoretic mobility. J Lipid Res. 1985;26:549-555.
24. Fielding PE, Kawano M, Catapano AL, Zoppo A, Marcovina S, Fielding CJ. Unique epitope of apolipoprotein A-I expressed in prebeta-1 high-density lipoprotein and its role in the catalyzed efflux of cellular cholesterol. Biochemistry. 1994;33:6981-6985.
25. O'Connor PM, Zysow BR, Schoenhaus SA, et al. Prebeta-1 HDL in plasma of normolipidemic individuals: influences of plasma lipoproteins, age, and gender. J Lipid Res. 1998;39:670-678.
26. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med. 1977;62:707-714.
27. Sethi AA, Sampson M, Warnick R, et al. High pre-1 HDL concentrations and low lecithin:cholesterol acyltransferase activities are strong positive risk markers for ischemic heart disease and independent of HDL-cholesterol. Clin Chem. 2010;56:1128-1137.
28. Glomset JA. The plasma lecithins:cholesterol acyltransferase reaction. J Lipid Res. 1968;9:155-167.
29. Nijstad N, Wiersma H, Gautier T, van der Giet M, Maugeais C, Tietge UJ. Scavenger receptor BI-mediated selective uptake is required for the remodeling of high density lipoprotein by endothelial lipase. J Biol Chem. 2009;284:6093-6100.
30. Barrans A, Collet X, Barbaras R, et al. Hepatic lipase induces the formation of pre-1 high density lipoprotein (HDL) from triacylglycerol-rich HDL2. A study comparing liver perfusion to in vitro incubation with lipases. J Biol Chem. 1994;269:11572-11577.
31. Wolfrum C, Poy MN, Stoffel M. Apolipoprotein M is required for pre-HDL formation and cholesterol efflux to HDL and protects against atherosclerosis. Nat Med. 2005;11:418-422.
32. Plomgaard P, Dullaart RP, de Vries R, Groen AK, Dahlbäck B, Nielsen LB. ApolipoproteinMpredicts pre-HDLformation: studies in type 2 diabetic and nondiabetic subjects. J Intern Med. 2009; 266:258-267.
33. Nielsen LB, Christoffersen C, Ahnstrom J, Dahlback B. ApoM: gene regulation and effects on HDL metabolism. Trends Endocrinol Metab. 2009;20:66-71.
34. Watson AD, Berliner JA, Hama SY, et al. Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin Invest. 1995;96:2882-2891.
35. Brousseau ME, Schaefer EJ, Wolfe ML, et al. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med. 2004;350:1505-1515.